Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2010 Aug 1;54(4):389–393. doi: 10.1097/QAI.0b013e3181c42ea4

Figure 2.

Figure 2

Evolution of integrase replicative capacity. Among subjects failing with integrase inhibitor resistance, there was a decrease in replicative capacity between pre-therapy baseline and the last failure time-point on drug (n=10, Panel A). Long-term virologic failure of an integrase inhibitor based regimen is associated with a decrease in replicative capacity (n=11, Panel B).